https://www.selleckchem.com/products/odm208.html
Identification of the dominant intraprostatic lesion(s) (DILs) can facilitate diagnosis and treatment by targeting biologically significant intra-prostatic foci. A PSMA ligand, [ F]DCFPyL (2-(3-1-carboxy-5-[(6-[ F]fluoro-pyridine-3-carbonyl)-amino]-pentyl-ureido)-pentanedioic acid), is better than choline-based [ F]FCH (fluorocholine) in detecting and localizing DIL because of higher tumour contrast, particularly when imaging is delayed to 1 h post-injection. The goal of this study was to investigate whether the different imaging perform
Like
Comment
Share
